Mirae Asset Capital Life Science
Mirae Asset Capital Life Science is a venture capital firm established in 2023, specializing in providing financial solutions for companies focused on life sciences. With investment professionals based in Boston and San Francisco, the firm targets therapeutics companies at various stages of development, from seed funding to Series C rounds. Mirae Asset Capital Life Science aims to support innovative companies that prioritize advancements in life science, contributing to the growth and evolution of the industry.
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and differentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.